Targeting TDP-43 to treat Alzheimer's disease and related disorders
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders
This study is looking at a protein called TDP-43 to see how it affects memory loss in Alzheimer's and similar conditions, and it's testing new medicines that might help keep this protein from clumping together, which could lead to better treatments for people with these diseases.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fox Chase Chemical Diversity Center, INC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project ID | NIH-10893509 on NIH RePORTER |
What this research studies
This research investigates the role of TDP-43 protein in Alzheimer's disease and related dementias, focusing on how TDP-43 inclusions correlate with cognitive decline. The team is exploring small molecules that can inhibit the aggregation of TDP-43, potentially leading to new therapeutic options. By understanding the mechanisms of TDP-43 in Alzheimer's, the research aims to develop targeted treatments that could improve cognitive function in affected individuals. Patients may be involved in trials assessing the safety and efficacy of these new therapies.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with Alzheimer's disease or related dementias, particularly those showing signs of TDP-43 involvement.
Not a fit: Patients with other forms of dementia not associated with TDP-43 pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and quality of life for patients with Alzheimer's disease.
How similar studies have performed: While targeting TDP-43 is a relatively novel approach, preliminary studies suggest that similar strategies may have shown promise in treating related neurodegenerative conditions.
Where this research is happening
Doylestown, United States
- Fox Chase Chemical Diversity Center, INC — Doylestown, United States (Active)
Researchers
- Principal investigator: Reitz, Allen Bernard — Fox Chase Chemical Diversity Center, INC
- Study coordinator: Reitz, Allen Bernard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.